Carbohydrate antigen 19-9 (also called as
cancer antigen 19-9; sialylated Lewis (a) antigen) is mainly increased in gastrointestinal system tumors.
Other tumour markers, such as
cancer antigen 19-9 (CA 19-9), may also be helpful indicators if initially elevated.
One final motive for studying these markers in the pediatric population is that there is early evidence that application of tumor markers such as
cancer antigen 19-9 (CA19-9), CA125, carcinoembryonic antigen (CEA), and [alpha]-fetoprotein (AFP) has value in various types of pediatric cancers, including yolk sac tumors and teratomas (3, 7).
Laboratory tests results were leukocyte count: 12.170/[mm.sup.3], C-reactive protein: 12.2 mg/L, carcinoembryonic antigen: <0.411 mg/L,
cancer antigen 19-9: 4.53 mg/L, and hemoglobin: 11 mg/L.
Levels of
cancer antigen 19-9 (CA 19-9) and cancer antigen 125 (CA-125) were within normal limits.
At admission,
cancer antigen 19-9 and carcinoembryonic antigen were within normal limits.
clinchem.org/content/vol60/issue2, the discriminatory performance of this marker (area under the curve, 0.86) was slightly better than that for
cancer antigen 19-9 (CA19-9) (area under the curve, 0.84).
CA 19-9 (
cancer antigen 19-9) or GICA (gastrointestinal cancer antigen) is a glycolipid with unknown biological function, which was the first successful tumour marker used for serological diagnosis of pancreatic cancer (90,91).
Serum human chorionic gonadotropin (HCG), Cancer Antigen 125 (CA125),
Cancer Antigen 19-9 (CA 19-9), alpha-fetoprotein (AFP) and lactate dehydogenase (LDH) were performed in 82%, 83%, 44%, 52%, 32%, respectively, and they were found to be elevated in 2%, 23%, 7%, 0% and 2% of the tested patients, respectively.
Serum
cancer antigen 19-9 (CA19-9; an antigen that is elevated in approximately 80 percent of patients with pancreatic cancer) was also measured for comparison.
Serum
cancer antigen 19-9 (CA19-9; an antigen that is elevated in approximately 80% of patients with pancreatic cancer) was also measured for comparison.
[1] Nonstandard abbreviations: CEA, carcinoembryonic antigen; CA 19-9,
cancer antigen 19-9.